Renaissance Capital logo

Rani Therapeutics Priced, Nasdaq: RANI

Develops ingestible capsules for oral dosing of medication.

Industry: Health Care

Latest Trade: $21.80 0.00 (0.0%)

First Day Return: 0.0%

Return from IPO: +98.2%

Industry: Health Care

We are a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics, which we believe have the potential to transform medicine and improve patient outcomes. We have developed the RaniPill capsule, which is our novel, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill approximately the size of a “000” capsule (or similar to the size of a standard fish oil or calcium pill) that is designed to automatically administer a precise therapeutic dose of medication upon deployment in the small intestine. To date, we have successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using the RaniPill capsule. Our development efforts have enabled us to construct an extensive intellectual property portfolio that we believe provides us a competitive advantage.
more less
IPO News for Rani Therapeutics
more
IPO Data
IPO File Date 07/09/2021
Offer Price $11.00
Price Range $14.00 - $16.00
Offer Shares (mm) 6.7
Deal Size ($mm) $73
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 07/30/2021
Offer Price $11.00
Price Range $14.00 - $16.00
Offer Shares (mm) 6.7
Deal Size ($mm) $73
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters San Jose, CA
Founded 2012
Employees 71
Website www.ranitherapeutics.com